Receptor Drug Discovery Research Articles

Development of a time-resolved fluorometric assay for the high throughput screening of melanin concentrating hormone receptor antagonists

Introduction Melanin concentrating hormone is an orexigenic hypothalamic neuropeptide, which plays an important role in the complex regulation of energy balance and body weight mediated by the melanin concentrating hormone receptor subtype 1 (MCH1). Compelling pharmacological evidence implicating MCH1 signaling in the regulation of food intake and energy expenditure has generated a great deal of interest by pharmaceutical companies as MCH1 antagonists may have potential therapeutic benefit in the treatment of obesity and metabolic syndrome. Methods Although radioligand receptor binding assay has been one of the most powerful tools for receptor research and drug discovery, the limitations of radioisotopes and the problems related to safety and waste disposal limits their application in high throughput screening and has led to a growing interest in alternative, nonradioactive technologies. To develop a sensitive and reproducible assay system for MCH1, the time-resolved fluorescence (TRF) receptor binding assay with AcroWell filter plates was tested and validated. Results Comparing to the radioligand receptor binding assay for MCH1, the TRF assay presented higher Z/ Z′ factors with the lower signal-to-noise ratio. The known high-affinity MCH1 receptor antagonist, SNAP-7941, exhibited an IC 50 value of 1.66 ± 0.10 nM that is very similar to the IC 50 value of MCH in a radioligand binding assay with an excellent correlation coefficient (0.9884). Discussion These results suggest that our TRF receptor binding assay for MCH1 can achieve the desired sensitivity and reproducibility to replace the radioligand receptor assay in a fluorometric system that can be developed for high throughput screening.

BacMam Recombinant Baculoviruses in G Protein?Coupled Receptor Drug Discovery

With completion of the sequencing of the human and mouse genomes, the primary sequences of close to 400 non-olfactory G protein-coupled receptors (GPCRs) have been determined. There are intensive efforts within the pharmaceutical industry to discover and develop new therapeutic agents acting via GPCRs. In addition, there is a concerted effort to identify potential new drug targets from the remaining 150+orphan GPCRs through the identification of their ligands. Access to functionally expressed recombinant receptors underpins both of these key drug discovery activities. Typically, GPCR drug discovery screening activities are carried out using mammalian cell lines stably expressing the target of interest. The influx of new receptor sequences originating from genomic sequencing efforts has caused a shift toward wider applications of transient rather than stable expression systems, especially in support of assays for orphan receptor ligand screening. Recombinant baculoviruses in which the polyhedrin promoter has been replaced with a mammalian promoter, termed BacMam viruses, were originally designed as potential new gene therapy delivery vehicles. This same technology offers numerous advantages as a transient expression system in the assay of membrane-expressed drug targets, including GPCRs. Data presented show that BacMam can be used rapidly to generate robust and pharmacologically authentic GPCR assays in several formats, with the potential to transform drug discovery screening processes for this gene family.

BacMam Recombinant Baculoviruses in G Protein–Coupled Receptor Drug Discovery

BacMam Recombinant Baculoviruses in G Protein–Coupled Receptor Drug Discovery

Bioinformatics for venom and toxin sciences.

Venomous animals produce a myriad of important pharmacological components. The individual components, or venoms (toxins), are used in ion channel and receptor studies, drug discovery, and formulation of insecticides. The toxin data are scattered across public databases which provide sequence and structural descriptions, but very limited functional annotation. The exponential growth of newly identified toxin data has created a need for better data management. Venominformatics is a systematic bioinformatics approach in which classified, consolidated and cleaned venom data are stored into repositories and integrated with advanced bioinformatics tools for the analysis of structure and function of toxins. Venominformatics complements experimental studies and helps reduce the number of essential experiments.

Cellular Fluorescent Indicators and Voltage/Ion Probe Reader (VIPR TM ): Tools for Ion Channel and Receptor Drug Discovery

Cellular Fluorescent Indicators and Voltage/Ion Probe Reader (VIPR TM ): Tools for Ion Channel and Receptor Drug Discovery

Cellular Fluorescent Indicators and Voltage/Ion Probe Reader (VIPR TM ): Tools for Ion Channel and Receptor Drug Discovery

High throughput functional assays are increasingly relied upon to generate early and novel discovery leads for drug development. Ion transport proteins including channels, transporters, and pumps play central roles in cellular bioenergetics, excitability, and a multitude of other biological functions. Facile, robust methods for detecting ion transport activity in both native and heterologous systems is desirable for rapid functional analysis and drug discovery for these difficult but important targets. Here we discuss cell-compatible fluorescent probes, functional assays, and VIPR instrumentation that are used to monitor real-time target activity and screen large chemical libraries for potent and selective modulators. Advances and issues for both exogenously applied and fluorescent protein probes of cellular membrane potential, Ca2+, Cl-, and pH are addressed. High throughput screening (HTS) compatible, rapid kinetic and fluorescence resonance energy transfer (FRET) assays are emphasized, in particular the use of voltage-sensitive FRET probes to assay ion channel activity in single cells and 96/384-well formats.

Combinatorial chemistry in steroid receptor drug discovery.

Combinatorial chemistry in steroid receptor drug discovery.

Development of a Fluorescent Ligand-Binding Assay Using the AcroWell Filter Plate

One of the most powerful tools for receptor research and drug discovery is the use of receptor–ligand affinity screening of combinatorial libraries. Early work involved the use of radioactive ligands to identify a binding event; however, there are numerous limitations involved in the use of radioactivity for high throughput screening. These limitations have led to the creation of highly sensitive, nonradioactive alternatives to investigate receptor–ligand interactions. Pall Gelman Laboratory has introduced the AcroWell, a patented low-fluorescent-background membrane and sealing process together with a filter plate design that is compatible with robotic systems. Taken together, these allow the AcroWell 96-well filter plate to detect trace quantities of lanthanide-labeled ligands for cell-, bead-, or membrane-based assays using time-resolved fluorescence. Using europium-labeled galanin, we have demonstrated that saturation binding experiments can be performed with low-background fluorescence and signal-to-noise ratios that rival traditional radioisotopic techniques while maintaining biological integrity of the receptor–ligand interaction. In addition, the ability to discriminate between active and inactive compounds in a mock galanin screen is demonstrated with low well-to-well variability, allowing reliable determination of positive hits even for low-affinity interactions.

Neurotransmitter receptor binding and drug discovery.

Neurotransmitter receptor binding and drug discovery.